<DOC>
	<DOC>NCT00243854</DOC>
	<brief_summary>To determine the feasibility and toxicity of neoadjuvant hypofractioned radiotherapy concurrently with weekly gemcitabine and an EGFR tyrosine-kinase inhibitor (OSI-774, Tarceva) in the treatment of patients with resectable pancreatic cancer.</brief_summary>
	<brief_title>Pilot Study Using Neoadj Chemo-Rad &amp; EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer</brief_title>
	<detailed_description>To determine the feasibility and toxicity of neoadjuvant hypofractioned radiotherapy concurrently with weekly gemcitabine and an EGFR tyrosine-kinase inhibitor (OSI-774, Tarceva) in the treatment of patients with resectable pancreatic cancer.</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>pathologically confirmed adenocarcinoma of the pancreas resectable disease tumor &lt;/= 6cm diameter ECOG performance 01 Organ system fxn: granulocytes (&gt;/=1800/uL); plt ct &gt;/=100K; bili&lt;/=2mg; liver enzymes &lt;2.5ULN; crt &lt;/=1.5; Normal CXR Negative pregnancy test metastatic disease or peritoneal seeding based on crosssectional imaging previous irradiation to the planned field prior chemotherapy or immunotherapy active infection active PUD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Resectable Pancreatic Cancer</keyword>
	<keyword>adenocarcinoma of the pancreas</keyword>
</DOC>